Dr Boreham's Crucible: Dimerix - FNArena.com
A positive trial result could put a rocket on shares in Dimerix, reports Tim Boreham, but investors won't know the answer until early 2024
Source: fnarena.com
📰 Dimerix Bioscience News
Dimerix Bioscience News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Dimerix Bioscience. Real-time updates on events, politics, business and more.
Effect of Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker Initiation on Organ Support–Free Days in Patients Hospitalized With COVID-19: A Randomized Clinical Trial | Critical Care Medicine | JAMA
This randomized clinical trial examines the effect of initiation of a renin-angiotensin system inhibitor (ACE inhibitor or an angiotensin receptor blocker) on t
Source: jamanetwork.com
DelveInsight Business Research, LLP: Extremely Robust Acute Respiratory Distress Syndrome Pipeline Featuring 100+ Companies Expected to Change the Pace of the ARDS Treatment
The rise in the incidence of ARDS stimulates the research and development of the drug, as it is likely to provide an appropriate environment for newer products to be profitable. Companies across
Prnewswire Delveinsight Inflammtory Demyelinating Polyneuropathy Verona Pharma Boehringer Ingelheim Genentech Synact Pharma Sarconeos Zavegepant
Source: finanznachrichten.de
Extremely Robust Acute Respiratory Distress Syndrome Pipeline Featuring 100+ Companies Expected to Change the Pace of the ARDS Treatment
The rise in the incidence of ARDS stimulates the research and development of the drug, as it is likely to provide an appropriate environment for newer products...
Synact Pharma Athersys Healios Verona Pharma Sarconeos Zavegepant Boehringer Ingelheim Genentech Chiesi Farmaceutici
Source: prnewswire.com
Chronic Obstructive Pulmonary Disease Clinical Trial
The rising incidence of COPD and the exacerbations associated with it have been instrumental in piquing the interest of pharma players and academia in...
Source: globenewswire.com